Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Hørselsnedsettelse, strategier og resultater i VA akuttavdelinger (HearVA-ED)

30. september 2026 oppdatert av: VA Office of Research and Development

Implementering av HearVA (I-HearVA)

HearVA involves six VA facility emergency departments (ED) over a 3-year intervention period. The first part of this study will test whether providing personal amplifiers to Veteran ED patients who self-report hearing difficulty is acceptable to these patients, can improve their hearing, enhance understanding of discharge instructions, and can reduce the risk of coming back to the ED in a short period of time (3 days and 30 days). The second part of the study will then identify whether ED staff can implement this program and achieve similar results. The second part will give ED staff increasing levels of responsibility for screening Veterans for hearing difficulty and providing personal amplifiers when such difficulty is detected.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

HearVA is a randomized controlled trial to explore the utility and outcomes of providing point-of-care access to hearing-impaired Veterans, comparing an offer of personal amplifiers versus control in an environment where the clinical stakes are high. It addresses a knowledge gap about the utility of providing such hearing assistance during clinical encounters. The study measures whether providing personal amplifiers is acceptable to older patients, can improve hearing, enhance understanding of discharge instructions, and improve care transitions at discharge. If such a strategy is beneficial, this simple low-tech approach has great potential for implementation and wide dissemination. HearVA-ED has two phases - the first, which has been completed, established the feasibility and acceptability of research and procedures in the ED environment through a pilot efficacy study and the second phase will be to complete a larger more definitive efficacy study and a detailed implementation study resulting in a strategic approach that can be widely disseminated across all VA emergency departments throughout the United States. This second phase will use a mixed-methods, hybrid effectiveness-implementation design to implement and evaluate the hearing assistance intervention in six VA Emergency Department Sites (in different facilities across the country). Implementation will occur in four stages with variation in the starting sequence at each site: The first group of two VA emergency departments will initiate implementation with an efficacy trial; second group of two sites will initiate implementation with delivery and support of personal amplifiers after screening and randomization by a research assistant (Stage 1); the third group of two sites will initiate implementation with the entire implementation (Stage 2) and the presence of a research assistant to conduct discharge interviews; and all sites will progress from this sequence to Stage 3 - Sustainability - which is the full implementation without research assistant presence.

Studietype

Intervensjonell

Registrering (Antatt)

1050

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

  • Navn: Lin T Tun
  • Telefonnummer: (646) 501-4132
  • E-post: lin.tun@va.gov

Studiesteder

    • Colorado
      • Aurora, Colorado, Forente stater, 80045-7211
        • Rekruttering
        • Rocky Mountain Regional VA Medical Center, Aurora, CO
        • Ta kontakt med:
    • New York
      • New York, New York, Forente stater, 10010-5011
        • Rekruttering
        • VA NY Harbor Healthcare System, New York, NY
        • Hovedetterforsker:
          • Joshua Chodosh, MD MSHS
        • Ta kontakt med:
        • Ta kontakt med:
      • Syracuse, New York, Forente stater, 13210-2716
        • Aktiv, ikke rekrutterende
        • Syracuse VA Medical Center, Syracuse, NY
      • The Bronx, New York, Forente stater, 10468
        • Rekruttering
        • James J. Peters VA Medical Center, Bronx, NY
        • Ta kontakt med:
    • North Carolina
      • Durham, North Carolina, Forente stater, 27705-3875
        • Rekruttering
        • Durham VA Medical Center, Durham, NC
        • Ta kontakt med:
    • Texas
      • Dallas, Texas, Forente stater, 75216-7167
        • Rekruttering
        • VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

60 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • English speaking
  • Emergency severity index criterion of 3 (medium), 4, or 5 (low acuity)
  • Hearing Handicap Inventory-Screen greater than or equal to 10 or positive answer to a single-item screening question
  • Capacity to consent to participate in research

Exclusion Criteria:

  • Inability to consent to participate in research
  • Emergency severity index criterion of 1-2 (high acuity)
  • Hearing Handicap Inventory-Screen less than 10 and negative answer to single item screening question
  • Inability to speak English
  • Using cochlear implants

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Intervention: Personal Amplifier

Consenting participants will be randomly assigned to the intervention group while receiving care in the emergency department

The intervention group will receive personal amplifiers (PockeTalkers) while they receive care in the ED

Andre navn:
  • Lommetaler
Annen: Control: No Personal Amplifier

Consenting participants will be randomly assigned to the control group while receiving care in the emergency department

The control group will not receive personal amplifiers while they receive care in the ED

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Emergency department (ED) 3-day Readmissions
Tidsramme: 3-5 days after initial ED stay

The Investigators will determine whether patients have had an ED revisit within three days through CPRS review as well as a brief follow-up phone call 3-5 days after ED discharge

3-5 days after initial ED stay

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Emergency department (ED) 30-day Readmissions
Tidsramme: 30-35 days after initial ED stay

The Investigators will determine whether patients have had an ED revisit within 30 days through CPRS review as well as a brief follow-up phone call 30-35 days after ED discharge

30-35 days after initial ED stay
Patient-Rated Quality of Hearing, Understanding, and Communication With Providers During Emergency department (ED) Stay
Tidsramme: Duration of ED stay, average of 1 day

Participants will self-rate their quality of hearing, understanding, and communication using a six item questionnaire. Scored on a 10-point Likert scale (1 = do not agree at all; 10 = completely agree) the questions will be: When I talked to the doctors and nurses today ... (1) their voices were very clear; (2) I was able to hear the sounds that I wanted to hear; (3) noises did not cause a problem for my hearing; and (4) listening did not make me tired. Two additional statements will explicitly capture understanding: (5) I was able to understand what they said; and (6) I was able to understand without making an effort. Higher scores will indicate better communication and understanding with providers.

Duration of ED stay, average of 1 day
Patient-Rated Quality of Post-Discharge Care
Tidsramme: At time of discharge from ED, average 1 day

Patient-rated quality of post-discharge care using a three-item subset of the Care Transition Measure (CTM). The questions are scored on a 1-4 scale (1= strongly disagree; 4 = strongly agree): (1) The ED staff considered my preferences and those of my family or caregiver in deciding what my healthcare needs were for discharge; (2) Leaving the ED, I have a good understanding of the things I am responsible for in managing my health; (3) Leaving the ED, I clearly understand the purpose for each of my medications. Higher scores will indicate better discharge preparation.

At time of discharge from ED, average 1 day
Self-Reported Understanding of Discharge Instructions
Tidsramme: 3-5 days after initial ED stay

Investigators will gauge self-reported understanding of discharge instructions using semi-structured interview data compared to documented discharge data.

3-5 days after initial ED stay

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Samarbeidspartnere

Etterforskere

  • Hovedetterforsker: Joshua Chodosh, MD MSHS, VA NY Harbor Healthcare System, New York, NY

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

8. desember 2021

Primær fullføring (Antatt)

31. mars 2027

Studiet fullført (Antatt)

31. mars 2027

Datoer for studieregistrering

Først innsendt

24. august 2021

Først innsendt som oppfylte QC-kriteriene

30. august 2021

Først lagt ut (Faktiske)

31. august 2021

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

5. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

30. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • IIR 17-068-1
  • HX002421 (Annet stipend/finansieringsnummer: VA HSR&D)
  • 5I01HX002421-08 (U.S. NIH-stipend/kontrakt)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .